Added value of biomarkers compared with clinical parameters for the prediction of radiographic spinal progression in axial spondyloarthritis

Rheumatology (Oxford). 2019 Sep 1;58(9):1556-1564. doi: 10.1093/rheumatology/kez025.

Abstract

Objectives: The objective of this study was to examine whether adding biomarkers to routine clinical parameters improves prediction of radiographic spinal progression in axial spondyloarthritis.

Methods: One hundred and seventeen patients with ankylosing spondylitis who completed the Effects of NSAIDs on RAdiographic Damage in Ankylosing Spondylitis (ENRADAS) trial were included. Radiographic spinal progression was defined as worsening of the modified Stoke Ankylosing Spondylitis Spine Score by ⩾2 points after 2 years. A clinical prediction model was constructed out of baseline syndesmophytes, elevated CRP, cigarette smoking and male sex. The following serum biomarkers were measured at baseline by ELISA: MMP3, VEGF, calprotectin, leptin, high molecular weight adiponectin, osteoprotegerin, sclerostin, N-terminal telopeptide, procollagen type II N-terminal propeptide and serum amyloid A.

Results: Repeated cross-validation analyses revealed one biomarker combination with potential added predictive value in addition to the clinical model: leptin + high molecular weight adiponectin + VEGF. This biomarker combination showed an area under the curve (AUC)Biomarkers = 0.731 (95% CI: 0.614, 0.848), which was numerically superior to the clinical model [AUCClinical = 0.665 (95% CI: 0.553, 0.776)]. A combination of clinical parameters + biomarkers showed an improved predictive value compared with the clinical model reflected by AUCClinical+Biomarkers = 0.768 (95% CI: 0.666, 0.871), though not statistically significant (P = 0.051). However, by considering the part of the receiver operating characteristic curve with a specificity ⩾75% resulting in partial AUC (pAUC), the improvement becomes significant (pAUCClinical+Biomarkers = 0.119; pAUCClinical = 0.053; P = 0.01).

Conclusion: Biomarkers show potential to improve the prediction of radiographic spinal progression in axial spondyloarthritis when used in addition to the clinical parameters, though the added value seems to be rather small.

Keywords: biomarkers; bone; cytokines and inflammatory mediators; radiology; spondyloarthritis; statistics.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Biomarkers / blood*
  • Disease Progression
  • Female
  • Humans
  • Inflammation Mediators / metabolism
  • Leptin / blood
  • Male
  • Middle Aged
  • Predictive Value of Tests
  • ROC Curve
  • Radiography
  • Severity of Illness Index
  • Spine / diagnostic imaging
  • Spondylitis, Ankylosing / diagnosis*
  • Spondylitis, Ankylosing / diagnostic imaging
  • Spondylitis, Ankylosing / drug therapy
  • Vascular Endothelial Growth Factor A / blood

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Biomarkers
  • Inflammation Mediators
  • LEP protein, human
  • Leptin
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A